Who are Self-Administered Nitrous Oxide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sulfate, Magnesium, Dextromethorphan Oral Solution, Nitrous Oxide/Oxygen, Magnesium Sulfate Infusion, Oxygen/nitrous oxide equimolar mix, IV Magnesium Sulfate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/self-administered-nitrous-oxide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Self-Administered Nitrous Oxide — Competitive Intelligence Brief

Self-Administered Nitrous Oxide (Self-Administered Nitrous Oxide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhalational anesthetic and analgesic. Area: Anesthesia and Pain Management.

marketed Inhalational anesthetic and analgesic NMDA receptor antagonist Anesthesia and Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Self-Administered Nitrous Oxide (Self-Administered Nitrous Oxide) — Beth Israel Deaconess Medical Center. Nitrous oxide acts as a dissociative anesthetic and analgesic by antagonizing N-methyl-D-aspartate (NMDA) receptors in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Self-Administered Nitrous Oxide TARGET	Self-Administered Nitrous Oxide	Beth Israel Deaconess Medical Center	marketed	Inhalational anesthetic and analgesic	NMDA receptor antagonist
Sulfate, Magnesium	Sulfate, Magnesium	Assistance Publique - Hôpitaux de Paris	marketed	Electrolyte supplement; anticonvulsant; smooth muscle relaxant	NMDA receptor antagonist; calcium channel blocker
Dextromethorphan Oral Solution	Dextromethorphan Oral Solution	Helsinki University Central Hospital	marketed	Non-opioid antitussive	NMDA receptor antagonist; sigma-1 receptor
Nitrous Oxide/Oxygen	Nitrous Oxide/Oxygen	Nationwide Children's Hospital	marketed	Inhalational anesthetic and analgesic gas	NMDA receptor antagonist; GABAergic potentiator
Magnesium Sulfate Infusion	Magnesium Sulfate Infusion	Ondokuz Mayıs University	marketed	Electrolyte supplement / anticonvulsant / tocolytic agent	NMDA receptor antagonist; calcium channel modulator
Oxygen/nitrous oxide equimolar mix	Oxygen/nitrous oxide equimolar mix	Hospital St. Joseph, Marseille, France	marketed	Inhalational anesthetic/analgesic gas mixture	NMDA receptor antagonist; endogenous opioid system modulation
IV Magnesium Sulfate	IV Magnesium Sulfate	University Hospitals Cleveland Medical Center	marketed	Electrolyte supplement / anticonvulsant	NMDA receptor antagonist; calcium channel blocker (non-selective)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhalational anesthetic and analgesic class)

Beth Israel Deaconess Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Self-Administered Nitrous Oxide — Competitive Intelligence Brief. https://druglandscape.com/ci/self-administered-nitrous-oxide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab